Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hymecromone in COVID-19
NCT05386420Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hymecromone + Conventional Treatment with Placebo + Conventional Treatment (2 arms). Primary endpoint: Proportion of subjects who developed disease progression at 28 days. Status: unknown.
02
Drugs
hymecromone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05386420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386420.